Department of Immunology, Tuberculosis Research Centre (ICMR), Chetput, Chennai-600 031, India,1 Department of Microbiology, Colorado State University, Fort Collins, Colorado 805232
Received 12 March 2001/ Returned for modification 14 June 2001/ Accepted 13 November 2001
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
The alarming increase in morbidity and mortality due to tuberculosis indicates the need to strengthen control measures. Control of the disease depends largely on early detection and treatment of active cases. There is promise in serodiagnostic tests like enzyme-linked immunosorbent assay (ELISA) because of their ease of performance and cost-effectiveness. Serodiagnosis was attempted in earlier days, using crude and semipurified antigens, and was found to give different ranges of sensitivity and specificity (10, 14). The results underline the importance of identifying species-specific antigens and using them for diagnosis.
Daniel and Anderson (12) were the first to report on the species-specific antigen 5 of Mycobacterium tuberculosis, which was later proved to be the same as the 38-kDa antigen. As antigen 5, it has shown high specificity in all studies conducted in different parts of the world (88 to 98%), while the sensitivity varied from 49 to 89% (2, 3, 13, 15, 23). Other than this and a limited number of other antigens, species specificity (at least M. tuberculosis complex specificity) is quite rare among the M. tuberculosis antigens.
In a preliminary study of immunoblots with patients' sera, we observed the specific recognition of a 16- or 17-kDa band by pooled tuberculous sera, which encouraged us to attempt the isolation of this protein. In the present study, the 16-kDa antigen has been purified from the cytosol fraction of M. tuberculosis H37Rv and evaluated for its diagnostic potential in the sera of various categories of tuberculosis patients by ELISA. Anti-16-kDa antibodies bound to the circulating immune complex (CIC) in the same groups of patients were also measured.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Sera were obtained from the various categories of patients and healthy individuals, as described below. A total of 555 sera were used in the study, 345 of which were obtained from pulmonary tuberculosis patients, which could be subdivided into the following groups. (i) Smear- and culture-positive cases, pretreatment (S+C+) (n = 175). Smear and culture examination were done according to standard procedures (1). Two spot and one overnight sputum specimens were collected from each patient, and direct smears stained for acid-fast bacilli were observed under a fluorescent microscope. The sputa were also decontaminated, concentrated, and inoculated on Lowenstein-Jenson medium and incubated for up to 8 weeks at 37°C to check positivity and negativity. (ii) Smear-negative, culture-positive cases, pretreatment (S-C+) (n = 41). (iii) Smear- and culture-negative, clinically and radiologically diagnosed cases (S-C- [X-ray]) (n = 50). The X rays were read by two independent readers (and by one more reader in case of disagreement between the two) and classified as possible or probable tuberculosis. This group formed part of a sample survey for prevalence of the disease in the community (16). (iv) Smear- and culture-negative cases, treated and remaining quiescent for at least 5 years (S-C- [treated]) (n = 79).
A total of 210 sera were obtained from controls, as follows. (i) Patients with nontuberculous lung diseases (non-TB) (n = 60). This category includes conditions that present with X-ray shadows, such as asthma, allergy, etc.; lung carcinoma; other infectious conditions likely to have cross-reactive antigens, such as nocardiasis; and patients with lung pathology in whom mycobacteria other than M. tuberculosis have been isolated. (ii) Healthy subjects from the laboratory and voluntary donors from a blood bank (HS) (n = 150).
The sera were aliquoted and stored at -70°C till the time of use.
Purification of 16-kDa antigen. M. tuberculosis H37Rv sonicate and cytosol antigens were prepared as described earlier (32).
The cytosol fraction of the sonicate antigen of M. tuberculosis H37Rv was passed through gel filtration chromatography using Ultrogel ACA34 matrix (Pharmacia, Uppsala, Sweden). Initially, 150 mg of the cytosol fraction was loaded on the gel filtration column (75 by 5 cm) along with bromophenol blue and blue dextran to serve as indicators for the mobility of samples. The elution was carried out with 20 mM Tris-HCl buffer along with 1 mM EDTA, 1 mM dithiothreitol, and 0.5 M NaCl at pH 8.2. The cytosol antigens separated by Ultrogel ACA34 were collected as 1-ml fractions at a rate of 0.75 ml per min. A total of 350 fractions were collected.
The quantification of the proteins was done with a bicinchoninic acid protein assay kit (Pierce, Rockford, Ill.).
Analytical SDS-PAGE. The cytosol and fractions were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) by the method of Laemmli (21), using a 12.5% resolving gel. After electrophoresis, the gels were stained with 0.2% Coomassie brilliant blue stain.
ELISA. ELISA was carried out to estimate the immunoglobulin G (IgG), IgA, and IgM antibody levels against the 16-kDa antigen of M. tuberculosis H37Rv as described previously (34). The coating concentration of antigen was 0.2 µg/ml. The sera were tested at 1/3,200.
CIC precipitation. The method of CIC precipitation with polyethylene glycol (PEG) has been described elsewhere (29). Reconstituted PEG precipitates (1/100 dilution) were tested for the presence of anti-16-kDa antibodies of the classes IgG, IgA, and IgM by ELISA.
In experiment 1, four categories of sera, namely, S+C+ (n = 20), S-C+(n = 26), S-C- (n = 37), and HS (n = 39) were randomly selected and subjected to CIC precipitation with 3.5% PEG. The CIC-bound 16-kDa antibodies were measured, and the number of positives in each category was calculated as before (greater than the mean plus 2 standard deviations [SD] of HS).
The experiment was repeated (experiment 2) with another set of sera (S+C+ [n = 20]. S-C+ [n = 26], S-C- [n = 27], and HS [n = 48]) to test reproducibility.
The results of experiments 1 and 2 were merged and analyzed.
| RESULTS |
|---|
|
|
|---|
|
The circular dichroism (CD) spectrum for the purified protein was analyzed and showed a maximum peak at 214 nm with a molar ellipticity of -65,779.9° cm2 · dmol-1, characteristic of ß-sheet structure (data not shown).
The identity of the purified 16-kDa antigen was established by an immunoblot with monoclonal antibodies (MAbs) IT-1 and IT-4 from the World Health Organization bank and a polyclonal antibody against H37Rv as a positive control. A positive reaction with the established MAbs suggests identity of this protein with the already reported 16-kDa antigen (data not shown).
Serum antibody levels. (i) Polar groups. The serum antibodies in the two polar groups, namely, the S+C+ and the HS groups, were measured. The mean optical densities (ODs) for IgG, IgA, and IgM obtained for the S+C+ group were 0.338, 0.367, and 0.453, respectively. In the case of the HS group, the mean ODs were observed to be 0.187, 0.162, and 0.373, respectively, which were significantly less (p = 0.0001) than those of the tuberculous patients.
Using a cutoff of greater than the mean plus 2 SD of HS, the sensitivities of the assay in S+C+ cases were 62.28, 52, and 10.85% for the three isotypes IgG, IgA, and IgM, respectively. The number and percentage of positives in the two polar groups are given in Table 1. The maximum number of positives was seen with IgG antibody. However, when individual results were scrutinized, it was observed that some sera negative for IgG were positive for IgA and/or IgM. By combining the results for IgG and IgA, the sensitivity of the assay was increased to 82.28%, while the specificity remained at 96.6%. When the results for IgM were also combined, the sensitivity was 82.85% and the specificity decreased to 93.3%.
|
For the S-C- (treated) cases, positivities of 20.25% (IgG), 25.31% (IgA), and 1.26% (IgM) were obtained. Among the non-TB lung disease cases, the percentages positive for 16-kDa antigen were 40, 10, and 1.66% for the three isotypes. The percentages positive in all these categories are shown in Table 2.
|
CIC-bound antibody to 16-kDa antigen. The results of experiments 1 and 2 were merged and are summarized in Table 3.
|
Out of the 60 sera from patients with non-TB lung diseases, 13 which were false positive for anti-16-kDa serum IgG and 7 which were negative were tested for CIC IgG. All serum positives but one proved to be negative for CIC-bound antibodies (results not shown).
| DISCUSSION |
|---|
|
|
|---|
The 16-kDa protein belongs to the alpha crystallin superfamily of small heat shock proteins and has been variously referred to as sHsp16, Hsp.16.3, Acr, and MPT63. It is similar to the major membrane protein (22) and Nox16 (18) referred to previously.
The antigen described in this study, isolated from the cytosol fraction, has been assigned a mass of 16 kDa based on its movement in SDS-PAGE. Further evidence for confirmation of the identity of this protein with Hsp. 16.3, reported earlier, comes from the study of the circular dichroism of this native protein. Our purified protein has been assigned a predominantly ß-sheet structure with a peak in the 210- to 215-nm region, which is in agreement with the report of Berengian et al. (4). Further, a positive reaction of this protein with MAbs IT-1 and IT-4 from the World Health Organization bank suggests the similarity of this 16-kDa protein to the reported 16-kDa Hsp antigen.
The antigen seems to exist in two different molecular forms, as two peaks at different RT were obtained from the purified antigen preparation when it was analyzed by HPLC. However, when the two peaks were separately analyzed by SDS-PAGE, both peaks contained only the 16-kDa protein, which shows that the protein exists in different oligomeric forms. Hsp.16.3 has been found to occur as oligomers consisting of a trimer of trimers (a nine-subunit complex) (11, 37).
The species specificity of this antigen has been extensively studied by various investigators. The mpt63 gene is found only in species of the M. tuberculosis complex, as shown by DNA hybridization studies (24). Antibodies against MPT63 do not cross-react with common environmental mycobacteria (24). Species-specific B-cell epitopes on this antigen have been demonstrated (19), and it has also been shown that its TB68 MAb-reacting epitope, as well as the T-cell clones, are specific for the M. tuberculosis complex (27). In a preliminary study of immunoblots with patients' sera, we have observed the specific recognition of a 16- or 17-kDa band by pooled tuberculous sera (n = 65) and not by pooled normal sera (n = 65), which also suggests the specificity of 16 kDa.
Effective serodiagnosis using 16-kDa antigen has been reported by previous investigators, though only a limited number of studies have been done with this antigen (22, 35). Other groups of workers have evaluated a 14-kDa antigen (which was later renamed Hsp16) and its epitopes (6, 20).
In all of the studies reported so far, only IgG has been measured, and the sensitivities ranged from 70 to 75%. In our study, a sensitivity of 62% was obtained in S+C+ cases by measuring IgG response alone, whereas when the IgA and IgM isotype response were combined, the sensitivity increased to 83%. Our sensitivity results show an improvement over those reported earlier, and the specificity (93%) is also comparable to those reported with other preparations of 16-kDa antigen.
In smear-negative cases, the sensitivity reported with this antigen was less. In the study conducted by Bothamley et al. (6), 46 and 11% sensitivities were obtained with 16-kDa whole antigen and the TB68 epitope, respectively. In another study, the 16-kDa antigen identified 54% of cases (20). In our study, using this antigen in the diagnosis of S-C+ patients, there was 39% positivity for the IgG and IgA isotypes and 10% positivity for the IgM isotype. By combining IgG, IgA, and IgM isotypes, the sensitivity was increased to 63.4%. A similarly high sensitivity of 74% was obtained for S-C- (X-ray) cases. Here again, an improvement in test outcome by combining three isotypes is demonstrated compared to IgG alone.
However, following a similar approach, the false positivity was very high (43%) in non-TB lung diseases. Cutoff limits of the mean plus 3 SD were used, and the results were recalculated. This did not eliminate the nonspecificity in this group, as 19 of 60 cases (31.7%) were still positive
Since the antigen is species specific, the false positivity may be attributed to nonspecific hyperglobulinemia, common in bronchial diseases (7), or other causes. Irrespective of the reason, this is a complicating factor in diagnosis and is likely to compromise the specificity of the assay when applied in clinical situations. Therefore, the value of the 16-kDa antigen for diagnosis based on serum antibodies is limited.
A large number of studies have reported the presence of CIC in tuberculous patients (8, 9, 25). Many of these studies measured the mycobacterial antigens (5, 25, 31) only after breaking the complex and concentrating them. Demonstration of antimycobacterial antibodies in CIC has posed fewer problems (5, 25, 31).
In one of our previous studies (29), we demonstrated that PEG-precipitable CICs are present in smear-positive, as well as smear-negative, patients' sera. In fact, the quantity of CIC (as judged by the OD at 280 nm) was significantly higher in smear-negative cases. Anti-mycobacterial-antibody measurement in CICs was more discriminatory between the groups than serum antibody measurement.
In the present study, we have measured CIC-bound antibodies of the classes IgG, IgA, and IgM against the 16-kDa antigen. While the majority of the CIC was IgG positive, IgA and IgM could also be measured. It was observed that many tuberculous sera, which were negative for free antibody, were positive for complexed antibody. Detection of anti-16-kDa antibodies in CIC greatly improved the outcome of the test, showing 97.5% sensitivity in the S+C+ group. Among S-C+ cases, too, 52 of 52 were positive for CIC antibodies, and among S-C- radiologically diagnosed cases, 45% were positive for CIC antibodies. Thus, these results reconfirm our previous observation of 100% sensitivity in culture-proven cases (29).
Out of the 60 sera from non-TB lung disease patients, 13 which were false positive for anti-16-kDa serum IgG and 7 which were negative were tested for CIC IgG. All serum positives but one proved to be negative for CIC-bound antibodies. Thus, the interfering serum component contributing to nonspecific high OD was removed. This is not a chance phenomenon, since we have also reported similar results for a 38-kDa antigen in the same study population (34).
The absence of antibody response to any particular antigen is generally interpreted as being due to immunosuppression or the absence of recognition due to host genetic factors. As early as 1980 (9), an inverse relationship between serum C1q binding and serum anti-Mycobacterium bovis BCG antibody was observed, suggesting that some antibodies may be bound to the complexes. Here, we have demonstrated that the absence of anti-16-kDa antibody in the free form could be due to its sequestration in the bound form.
Earlier studies by other authors have reported the detection of CIC antibodies against glycolipid antigens (phosphatidyl inositomannoside and diacyl trehalose), as well as protein antigens (antigen 5) (26, 28, 33). The diagnostic value of anti-16-kDa CIC antibodies has not been reported so far. Our study has demonstrated a high sensitivity of detection of S+ cases, as well as S- cases, where diagnosis is most needed. The CIC antibody-based diagnosis, owing to its high sensitivity and specificity, can be useful for (i) individual patient-based diagnosis; (ii) detection of cases under Tuberculosis Control Program conditions, compared to sputum smears; and (iii) detection of cases while screening populations, compared to X rays.
The method involves overnight incubation, centrifugation, etc. Therefore, it cannot be viewed as a rapid test to be performed under field conditions. However, a large number of samples can be brought to a central laboratory and processed together. As for the time involved in incubation, the test is comparable to the sputum smear, since at least three sputum collections from the same patient (two spot and one overnight) are to be tested under Tuberculosis Control Program conditions. Even then, false negativity can be seen in the smear test, which is overcome by CIC ELISA. (In the present study, sputum smears diagnosed 175 out of 216 [81%] culture-positive cases, while CIC ELISA identified 91 of 92 (98.9%) culture-positive cases.) Although three isotypes have to be measured, they can be combined in a single test, since anti-human IgG-IgA-IgM conjugates are commercially available. This test will be especially useful in cases where sputum positivity is rare, such as childhood tuberculosis, extrapulmonary tuberculosis, and minimal disease.
| ACKNOWLEDGMENTS |
|---|
K. R. Uma Devi is the recipient of a Junior Research Fellowship from the Department of Biotechnology, Government of India. B. Ramalingam is the recipient of a Senior Research Fellowship from the Council of Scientific and Industrial Research, New Delhi, India.
We are thankful to K. N. Sulochana, Department of Biochemistry, Vision Research Foundation, Chennai, India, and R. Jayakumar, Department of Bio-Organic Chemistry, Central Leather Research Institute, Chennai, India, for providing the facilities for HPLC and CD, respectively.
| FOOTNOTES |
|---|
| REFERENCES |
|---|
|
|
|---|
-crystallin domain of small heat-shock proteinscomparison of the oligomer symmetry in
-crystallin, HSP 27 and HSP 16.3. J. Biol. Chem. 274:6305-6314.
-crystallin homolog by exposure to nitric oxide donors. Infect. Immun. 67:460-465.
-crystallin family of low-molecular-weight heat shock proteins. J. Bacteriol. 174:1352-1359.
-crystallin homolog. J. Bacteriol. 178:4484-4492.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. | Infect. Immun. |
|---|---|---|
| J. Clin. Microbiol. | J. Virol. | ALL ASM JOURNALS |